Clinical Trial Update: SLM + Axitinib for Clear Cell RCC [Phase 1]

View source ↗

Summary

Clinical trial update reports completion of a Phase 1 study evaluating SLM in combination with axitinib for advanced/metastatic clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• SLM

Snippet

Sponsor: Mohammed Milhem | Conditions: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) | Phase 1 | Status: COMPLETED